Advertisement

Pharmaceutical Research

, Volume 33, Issue 11, pp 2777–2793 | Cite as

Effect of the Freezing Step in the Stability and Bioactivity of Protein-Loaded PLGA Nanoparticles Upon Lyophilization

  • Pedro FonteEmail author
  • Fernanda Andrade
  • Cláudia Azevedo
  • João Pinto
  • Vítor Seabra
  • Marco van de Weert
  • Salette Reis
  • Bruno SarmentoEmail author
Research Paper

Abstract

Purpose

The freezing step in lyophilization is the most determinant for the quality of biopharmaceutics. Using insulin as model of therapeutic protein, our aim was to evaluate the freezing effect in the stability and bioactivity of insulin-loaded PLGA nanoparticles. The performance of trehalose, sucrose and sorbitol as cryoprotectants was evaluated.

Methods

Cryoprotectants were co-encapsulated with insulin into PLGA nanoparticles and lyophilized using an optimized cycle with freezing at −80°C, in liquid nitrogen, or ramped cooling at −40°C. Upon lyophilization, the stability of protein structure and in vivo bioactivity were assessed.

Results

Insulin was co-encapsulated with cryoprotectants resulting in particles of 243–394 nm, zeta potential of −32 to −35 mV, and an association efficiency above 90%. The cryoprotectants were crucial to mitigate the freezing stresses and better stabilize the protein. The insulin structure maintenance was evident and close to 90%. Trehalose co-encapsulated insulin-loaded PLGA nanoparticles demonstrated enhanced hypoglycemic effect, comparatively to nanoparticles without cryoprotectant and added with trehalose, due to a superior insulin stabilization and bioactivity.

Conclusions

The freezing process may be detrimental to the structure of protein loaded into nanoparticles, with negative consequences to bioactivity. The co-encapsulation of cryoprotectants mitigated the freezing stresses with benefits to protein bioactivity.

KEY WORDS

cryoprotectant freezing insulin lyophilization PLGA nanoparticles 

Abbreviations

AAC

Area above the curve

AE

Association efficiency

ATR-FTIR

Attenuated Total Reflectance-Fourier transform infrared spectroscopy

CD

Circular dichroism

DSC

Differential scanning calorimetry

HPLC

High performance liquid chromatography

LC

Loading capacity

PA

Pharmacological availability

PLGA

Poly(lactic-co-glycolic acid)

PVA

Polyvinyl alcohol

RE

Retention efficiency

SEM

Scanning electron microscopy

Tc

Collapse temperature

Tg

Glass transition temperature

Tg’

Glass transition temperature of the frozen sample

XRPD

X-Ray powder diffraction

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

Pedro Fonte and Fernanda Andrade would like to thank Fundação para a Ciência e a Tecnologia (FCT), Portugal (PTDC/SAL-FCT/104492/2008; SFRH/BD/78127/2011) and (SFRH/BD/73062/2010) for financial support. This work was also financed by European Regional Development Fund (ERDF) through the Programa Operacional Factores de Competitividade − COMPETE, by Portuguese funds through FCT in the framework of the project PEst-C/SAU/LA0002/2013, and cofinanced by North Portugal Regional Operational Programme (ON.2 − O Novo Norte) in the framework of Project SAESCTN-PIIC&DT/2011 under the National Strategic Reference Framework (NSRF). It is also acknowledged the financial support from FCT/MEC through national funds and co-financed by FEDER, under the Partnership Agreement PT2020 (UID/MULTI/04378/2013 - POCI/01/0145/FERDER/007728). Abbot Laboratories, Portugal is acknowledged for kindly provide the Precision Xtra® blood glucose meter and test strips. The authors also thank to Dorthe Ørbæk from the Faculty of Health and Medical Sciences, University of Copenhagen, for the XRPD experiments.

Supplementary material

11095_2016_2004_MOESM1_ESM.docx (561 kb)
ESM 1 (DOCX 561 kb)

References

  1. 1.
    Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Fonte P, Araujo F, Silva C, Pereira C, Reis S, Santos HA, et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol Adv. 2015;33:1342–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Konan Y, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm. 2002;233:239–52.CrossRefPubMedGoogle Scholar
  4. 4.
    De Jaeghere F, Allemann E, Leroux J, Stevels W, Feijen J, Doelker E, et al. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res. 1999;16:859–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Williams NA, Polli GP. The lyophilization of pharmaceuticals: a literature review. J Parenter Sci Technol. 1984;38:48–59.PubMedGoogle Scholar
  6. 6.
    Franks F. Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm. 1998;45:221–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Kasper JC, Friess W. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm. 2011;78:248–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Izutsu K, Fujimaki Y, Kuwabara A, Aoyagi N. Effect of counterions on the physical properties of l-arginine in frozen solutions and freeze-dried solids. Int J Pharm. 2005;301:161–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Heller M, Carpenter J, Randolph T. Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation. Biotechnol Bioeng. 1999;63:166–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Kadoya S, Fujii K, Izutsu K, Yonemochi E, Terada K, Yomota C, et al. Freeze-drying of proteins with glass-forming oligosaccharide-derived sugar alcohols. Int J Pharm. 2010;389:107–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Searles J. Freezing and annealing phenomena in lyophilization. In: Rey L, May JC, editors. Freeze drying/lyophilization of pharmaceutical and biological products. Informa Healthcare; 2010. p. 52–81.Google Scholar
  12. 12.
    Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12:505–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Sameti M, Bohr G, Ravi Kumar MNV, Kneuer C, Bakowsky U, Nacken M, et al. Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int J Pharm. 2003;266:51–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688–713.CrossRefPubMedGoogle Scholar
  16. 16.
    Fonte P, Soares S, Sousa F, Costa A, Seabra V, Reis S, et al. Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles. Biomacromolecules. 2014;15:3753–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Fonte P, Araújo F, Seabra V, Reis S, van de Weert M, Sarmento B. Co-encapsulation of lyoprotectants improves the stability of protein-loaded PLGA nanoparticles upon lyophilization. Int J Pharm. 2015;496:850–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr. 2006;20:898–903.CrossRefPubMedGoogle Scholar
  19. 19.
    Dong A, Huang P, Caughey W. Protein secondary structures in water from second-derivative amide i infrared spectra. Biochemistry. 1990;29:3303–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Kendrick B, Dong A, Allison S, Manning M, Carpenter J. Quantitation of the area of overlap between second-derivative amide I infrared spectra to determine the structural similarity of a protein in different states. J Pharm Sci. 1996;85:155–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Maltesen M, Bjerregaard S, Hovgaard L, Havelund S, Van De Weert M. Analysis of insulin allostery in solution and solid state with FTIR. J Pharm Sci. 2009;98:3265–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Fonte P, Soares S, Costa A, Andrade J, Seabra V, Reis S, et al. Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter. 2012;2:329–39.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Matsumoto S. Proteins and sugars affecting the zeta potential and stability of dispersed vesicular globules in w/o/w emulsions. In: Nishinari K, Doi E, editors. Food hydrocolloids. US: Springer; 1993. p. 399–408.Google Scholar
  24. 24.
    Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm Biopharm. 2006;63:87–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int J Pharm. 2006;309:178–88.CrossRefPubMedGoogle Scholar
  26. 26.
    Tang X, Pikal M. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21:191–200.CrossRefPubMedGoogle Scholar
  27. 27.
    Pikal MJ, Shah S, Roy ML, Putman R. The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int J Pharm. 1990;60:203–7.CrossRefGoogle Scholar
  28. 28.
    Pikal M, Shah S. The collapse temperature in freeze drying: dependance on measurement methodology and rate of water removal from the glassy state. Int J Pharm. 1990;62:165–86.CrossRefGoogle Scholar
  29. 29.
    Schwegman JJ, Carpenter JF, Nail SL. Evidence of partial unfolding of proteins at the ice/freeze-concentrate interface by infrared microscopy. J Pharm Sci. 2009;98:3239–46.CrossRefPubMedGoogle Scholar
  30. 30.
    Searles JA, Carpenter JF, Randolph TW. The ice nucleation temperature determines the primary drying rate of lyophilization for samples frozen on a temperature-controlled shelf. J Pharm Sci. 2001;90:860–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Bozdag S, Dillen K, Vandervoort J, Ludwig A. The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D, L-lactide-glycolide) nanoparticles. J Pharm Pharmacol. 2005;57:699–707.CrossRefPubMedGoogle Scholar
  32. 32.
    Liu J, Viverette T, Virgin M, Anderson M, Paresh D. A study of the impact of freezing on the lyophilization of a concentrated formulation with a high fill depth. Pharm Dev Technol. 2005;10:261–72.CrossRefPubMedGoogle Scholar
  33. 33.
    Patapoff TW, Overcashier DE. The importance of freezing on lyophilization cycle development. BioPharm. 2002;15:16–21.Google Scholar
  34. 34.
    Webb SD, Cleland JL, Carpenter JF, Randolph TW. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma. J Pharm Sci. 2003;92:715–29.CrossRefPubMedGoogle Scholar
  35. 35.
    Pikal MJ, Rigsbee DR. The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm Res. 1997;14:1379–87.CrossRefPubMedGoogle Scholar
  36. 36.
    Sarmento B, Ferreira D, Jorgensen L, van de Weert M. Probing insulin’s secondary structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm. 2007;65:10–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Strambini GB, Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys J. 1996;70:971–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Sarciaux JM, Mansour S, Hageman MJ, Nail SL. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J Pharm Sci. 1999;88:1354–61.CrossRefPubMedGoogle Scholar
  39. 39.
    Eckhardt BM, Oeswein JQ, Bewley TA. Effect of freezing on aggregation of human growth hormone. Pharm Res. 1991;8:1360–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci. 1996;85:1325–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Nema S, Avis KE. Freeze-thaw studies of a model protein, lactate dehydrogenase, in the presence of cryoprotectants. J Parenter Sci Technol. 1993;47:76–83.PubMedGoogle Scholar
  42. 42.
    Carpenter JF, Arakawa T, Crowe JH. Interactions of stabilizing additives with proteins during freeze-thawing and freeze-drying. Dev Biol Stand. 1992;74:225–38. discussion 238–229.PubMedGoogle Scholar
  43. 43.
    Griebenow K, Klibanov A. On protein denaturation in aqueous−organic mixtures but not in pure organic solvents. J Am Chem Soc. 1996;118:11695–700.CrossRefGoogle Scholar
  44. 44.
    Van de Weert M, Hering J, Haris P. Fourier transform infrared spectroscopy. In: Jiskoot W, Crommelin D, editors. Methods for structural analysis of protein pharmaceuticals. AAPS Press; 2005. p. 131–166.Google Scholar
  45. 45.
    Jørgensen L, Vermehren C, Bjerregaard S, Froekjaer S. Secondary structure alterations in insulin and growth hormone water-in-oil emulsions. Int J Pharm. 2003;254:7–10.CrossRefPubMedGoogle Scholar
  46. 46.
    Kelly S, Jess T, Price N. How to study proteins by circular dichroism. Biochim Biophys Acta. 2005;1751:119–39.CrossRefPubMedGoogle Scholar
  47. 47.
    Yong Z, Yingjie D, Xueli W, Jinghua X, Zhengqiang L. Conformational and bioactivity analysis of insulin: freeze-drying TBA/water co-solvent system in the presence of surfactant and sugar. Int J Pharm. 2009;371:71–81.CrossRefGoogle Scholar
  48. 48.
    Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 2000;9:1960–7.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ahmad A, Uversky VN, Hong D, Fink AL. Early events in the fibrillation of monomeric insulin. J Biol Chem. 2005;280:42669–75.CrossRefPubMedGoogle Scholar
  50. 50.
    Bekard IB, Dunstan DE. Tyrosine autofluorescence as a measure of bovine insulin fibrillation. Biophys J. 2009;97:2521–31.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Falconi M, Bozzi M, Paci M, Raudino A, Purrello R, Cambria A, et al. Spectroscopic and molecular dynamics simulation studies of the interaction of insulin with glucose. Int J Biol Macromol. 2001;29:161–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Amidi M, Pellikaan HC, de Boer AH, Crommelin DJ, Hennink WE, Jiskoot W. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur J Pharm Biopharm. 2008;68:191–200.CrossRefPubMedGoogle Scholar
  53. 53.
    Malik R, Roy I. Probing the mechanism of insulin aggregation during agitation. Int J Pharm. 2011;413:73–80.CrossRefPubMedGoogle Scholar
  54. 54.
    Lakowicz JR. Principles of fluorescence spectroscopy. US: Springer; 2006.CrossRefGoogle Scholar
  55. 55.
    Arigita C, Jiskoot W, Westdijk J, van Ingen C, Hennink WE, Crommelin DJ, et al. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine. 2004;22:629–42.CrossRefPubMedGoogle Scholar
  56. 56.
    LeVine H. Thioflavine T interaction with amyloid β-sheet structures. Amyloid. 1995;2:1–6.CrossRefGoogle Scholar
  57. 57.
    Maskevich AA, Stsiapura VI, Kuzmitsky VA, Kuznetsova IM, Povarova OI, Uversky VN, et al. Spectral properties of thioflavin t in solvents with different dielectric properties and in a fibril-incorporated form. J Proteome Res. 2007;6:1392–401.CrossRefPubMedGoogle Scholar
  58. 58.
    Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 2001;40:6036–46.CrossRefPubMedGoogle Scholar
  59. 59.
    Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci U S A. 2002;99:9196–201.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.UCIBIO, REQUIMTE, Department of Chemical Sciences - Applied Chemistry Lab, Faculty of PharmacyUniversity of PortoPortoPortugal
  2. 2.CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeGandra PRDPortugal
  3. 3.Laboratory of Pharmaceutical Technology, Faculty of PharmacyUniversity of PortoPortoPortugal
  4. 4.IBEC, Institute for Bioengineering of CataloniaBarcelonaSpain
  5. 5.School of PharmacyUniversity of BarcelonaBarcelonaSpain
  6. 6.i3S, Instituto de Investigação e Inovação em SaúdeUniversidade do PortoPortoPortugal
  7. 7.INEB - Instituto de Engenharia BiomédicaUniversidade do PortoPortoPortugal
  8. 8.iMed. ULisboa, Department of Galenic Pharmacy and Pharmaceutical Technology, Faculty of PharmacyUniversity of LisbonLisbonPortugal
  9. 9.Department of Pharmacy, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations